Protein expression profiles indicative for drug resistance of non-small cell lung cancer

被引:0
|
作者
M Volm
R Koomägi
J Mattern
T Efferth
机构
[1] German Cancer Research Centre,
[2] Virtual Campus Rhineland-Palatinate,undefined
来源
British Journal of Cancer | 2002年 / 87卷
关键词
non-small cell lung carcinomas; resistance factors; hierarchical cluster analysis;
D O I
暂无
中图分类号
学科分类号
摘要
Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising expression profiles may predict drug resistance with higher accuracy than single gene or protein expression studies. Forty cellular parameters (drug resistance proteins, proliferative, apoptotic, and angiogenic factors, products of proto-oncogenes, and suppressor genes) were evaluated mainly by immunohistochemistry in specimens of primary non-small cell lung carcinoma of 94 patients and compared with the response of the tumours to doxorubicin in vitro. The protein expression profile of non-small cell lung carcinoma was determined by hierarchical cluster analysis and clustered image mapping. The cluster analysis revealed three different resistance profiles. The frequency of each profile was different (77, 14 and 9%, respectively). In the most frequent drug resistance profile, the resistance proteins P-glycoprotein/MDR1 (MDR1, ABCB1), thymidylate-synthetase, glutathione-S-transferase-π, metallothionein, O6-methylguanine-DNA-methyltransferase and major vault protein/lung resistance-related protein were up-regulated. Microvessel density, the angiogenic factor vascular endothelial growth factor and its receptor FLT1, and ECGF1 as well were down-regulated. In addition, the proliferative factors proliferating cell nuclear antigen and cyclin A were reduced compared to the sensitive non-small cell lung carcinoma. In this resistance profile, FOS was up-regulated and NM23 down-regulated. In the second profile, only three resistance proteins were increased (glutathione-S-transferase-π, O6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). The angiogenic factors were reduced. In the third profile, only five of the resistance factors were increased (MDR1, thymidylate-synthetase, glutathione-S-transferase-π, O6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein).
引用
收藏
页码:251 / 257
页数:6
相关论文
共 50 条
  • [41] SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer
    Lu, Weidong
    Zuo, Yun
    Feng, Yufang
    Zhang, Min
    TUMOR BIOLOGY, 2014, 35 (11) : 10699 - 10705
  • [42] Gene Expression Profiles of Non-Small Cell Lung Cancer: Survival Prediction and New Biomarkers
    Vaelk, Kristjan
    Vooder, Tonu
    Kolde, Raivo
    Reintam, Mari-Ann
    Petzold, Cathleen
    Vilo, Jaak
    Metspalu, Andres
    ONCOLOGY, 2010, 79 (3-4) : 283 - 292
  • [43] New Drug for Squamous Non-Small Cell Lung Cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2016, 116 (03) : 22 - 23
  • [44] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [45] Drug therapy of metastasized non-small cell lung cancer
    Heigener, D. F.
    Reinmuth, N.
    Reck, M.
    PNEUMOLOGE, 2016, 13 (01): : 65 - 72
  • [46] Drug treatment of metastasized non-small cell lung cancer
    Leipert, Jenny
    Hammerschmidt, Stefan
    Gessner, Christian
    PNEUMOLOGE, 2019, 16 (06): : 397 - 409
  • [47] Antibody Drug Conjugates for Non-small Cell Lung Cancer
    Hayashi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S830 - S830
  • [48] Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer
    Oshika, Y
    Nakamura, M
    Tokunaga, T
    Fukushima, Y
    Abe, Y
    Ozeki, Y
    Yamazaki, H
    Tamaoki, N
    Ueyama, Y
    MODERN PATHOLOGY, 1998, 11 (11) : 1059 - 1063
  • [49] Role of long non-coding RNA in drug resistance in non-small cell lung cancer
    Wang, Leirong
    Ma, Leina
    Xu, Fei
    Zhai, Wenxin
    Dong, Shenghua
    Yin, Ling
    Liu, Jia
    Yu, Zhuang
    THORACIC CANCER, 2018, 9 (07) : 761 - 768
  • [50] Isoform specific expression of cadherin10 is associated with progression and drug resistance in non-small cell lung cancer
    Ghosh, Rajib
    Powan, Phattrakorn
    Rojanasakul, Liying W.
    Rojanasakul, Yon
    CANCER RESEARCH, 2019, 79 (13)